The year in interventional cardiology

Journal of the American College of Cardiology

Volumn 43, Issue 5, 2004, Pages 875-890

  O'Neill, William W ^a   Dixon, Simon R ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; ABCIXIMAB; ABT 578; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; EVEROLIMUS; FENOLDOPAM MESILATE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; PACLITAXEL; PEXELIZUMAB; POLITEF; RAPAMYCIN; TICLOPIDINE; TIROFIBAN;

ACUTE DISEASE; ACUTE HEART INFARCTION; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING STENT; DRUG MEGADOSE; EMBOLISM; FIBRINOLYTIC THERAPY; HEART ASSIST DEVICE; HEART CATHETERIZATION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; KIDNEY DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ST SEGMENT ELEVATION; THROMBECTOMY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; CONTRAST MEDIA; CORONARY DISEASE; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; EQUIPMENT DESIGN; FILTRATION; FORECASTING; HEART DISEASES; HUMANS; KIDNEY DISEASES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; STENTS;

EID: 1542271668     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.12.024     Document Type: Review

References (93)

1. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction a quantitative review of 23 randomised trials. Lancet. 361:2003;13-20.
2. The PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction six-month follow-up and analysis of individual patient data from randomized trials. Am Heart J. 145:2003;47-57.
3. Grzybowski M., Clements E.A., Parsons L., et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy. JAMA. 290:2003;1891-1898.
4. Andersen H.R., Nielsen T.T., Rasmussen K., et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 349:2003;733-742.
5. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial - PRAGUE-2. Eur Heart J 2003;94-104.
6. Schomig A., Ndrepepa G., Mehilli J., et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. Circulation. 108:2003;1084-1088.
7. Gibson C.M., Karha J., Murphy S.A., et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis In Myocardial Infarction trials. J Am Coll Cardiol. 42:2003;7-16.
8. Dalby M., Bouzamondo A., Lechat P., Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction a meta-analysis. Circulation. 108:2003;1809-1814.
9. Topol E.J., Califf R.M., George B.S., et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 317:1987;581-588.
10. Simoons M.L., Arnold A.E.R., Betriu A., et al. Thrombolysis with t-PA in acute myocardial infarction no beneficial effects of immediate PTCA. Lancet. 1:1988;197-203.
11. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction TIMI IIA results. JAMA. 260:1988;2849-2858.
12. Scheller B., Hennen B., Hammer B., et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 42:2003;634-641.
13. Dauerman H.L., Sobel B.E. Synergistic treatment of ST-segment elevation myocardial infarction with pharmacoinvasive recanalization. J Am Coll Cardiol. 42:2003;646-651.
14. Fernandez-Aviles F, GRACIA Group. Primary optimal percutaneous coronary intervention versus facilitated intervention (tenecteplase plus stenting) in patients with ST-elevated acute myocardial infarction (GRACIA-2). Presented at the European Society of Cardiology Congress 2003, Vienna, Austria, September 2003.
15. Kastrati A, Mehilli J, Schlotterbeck K, et al., for the BRAVE Investigators. A randomized evaluation of early administration of reteplase plus abciximab or abciximab alone prior to percutaneous coronary intervention in patients with acute myocardial infarction. Presented at the Annual Scientific Session of the American Heart Association, Orlando, Florida, November 2003.
16. Topol E.J., Neumann F.J., Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 42:2003;1886-1888.
17. Antoniucci D., Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 42:2003;1879-1885.
18. Tcheng J.E., Kandzari D.E., Grines C.L., et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation. 108:2003;1316-1323.
19. van't Hof A, on behalf of the ON-TIME Investigators. Does pre-transportation treatment with tirofiban improve patency in acute myocardial infarction patients who are referred for percutaneous coronary intervention (ON-TIME)? Presented at the European Society of Cardiology Congress 2003, Vienna, Austria, September 2003.
20. Lee D.P., Herity N.A., Hiatt B.L., et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes. Circulation. 107:2003;1497-1501.
21. Granger C.B., Maheffey K.W., Weaver D., et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction. Circulation. 108:2003;1184-1190.
22. Kopecky S.L., Aviles R.J., Bell M.R., et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size in patients undergoing primary percutaneous transluminal coronary angioplasty the ADMIRE (AmP59 Delivery for Myocardial Infarction Reduction) study. Am Heart J. 146:2003;146-152.
23. van der Horst I.C., Zijlstra F., van't Hof A.W.J., et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 42:2003;784-791.
24. O'Neill WW, on behalf of the COOL-MI Investigators. A prospective, randomized trial of mild systemic hypothermia during PCI treatment of ST elevation MI. Presented at Transcatheter Cardiovascular Therapeutics 2003, Washington, DC, September 2003.
25. Napodano M., Pasquetto G., Sacca S., et al. Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 42:2003;1395-1402.
26. Lefevre T, Ludwig J, on behalf of the XAMINE ST Investigators. X-Sizer in AMI patients for negligible embolization and optimal ST resolution. Presented at Transcatheter Cardiovascular Therapeutics 2003, Washington, DC, September 2003.
27. Limbruno U., Micheli A., de Carlo M., et al. Mechanical prevention of distal embolization during primary angioplasty safety, feasibility and impact on myocardial reperfusion. Circulation. 108:2003;171-176.
28. Henriques J.P.S., Haasdiijk A.P., Zijlstra F., et al. Outcome of primary angioplasty for acute myocardial infarction during routine duty hours versus during off-hours. J Am Coll Cardiol. 41:2003;2138-2142.
29. The FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease FRISC II randomised multicenter study. Lancet. 354:1999;708-715.
30. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 344:2001;1879-1887.
31. Fox K.A., Poole-Wilson P.A., Henderson R.A., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction the British Heart Foundation RITA-3 randomised trial. Lancet. 360:2002;743-751.
32. Barrabes J.A., Figueras J., Moure C., Cortadellas J., Soler-Soler J. Prognostic value of lead aVR in patients with a first non-ST-segment elevation acute myocardial infarction. Circulation. 108:2003;814-819.
33. Neumann F.J., Kastrati A., Pogatsa-Murray G., et al. Evaluation of prolonged antithrombotic pretreatment ('cooling-off' strategy) before intervention in patients with unstable coronary syndromes a randomized controlled trial. JAMA. 290:2003;1593-1599.
34. Sousa J.E., Costa M.A., Abizaid A., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 103:2001;192-195.
35. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 346:2002;1773-1780.
36. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 349:2003;1315-1323.
37. Schofer J., Schluter M., Gershlick A., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries double-blind, randomized controlled trial (E-SIRIUS). Lancet. 362:2003;1093-1099.
38. Grube E. FUTURE II: multicenter evaluation of the bioabsorbable polymer-based everolimus-eluting stent. Presented at Transcatheter Cardiovascular Therapeutics 2003, Washington, DC, September 2003.
39. Sousa J.E., Costa M.A., Abizaid A., et al. Sirolimus-eluting stent for the treatment of in-stent restenosis. Circulation. 107:2003;24-27.
40. Degertekin M, Regar E, Tanabe, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis. J Am Coll Cardiol 2003;41:184-9.
41. Saia F., Lemos P.A., Lee C.H., et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction. Circulation. 108:2003;1927-1929.
42. Lemos P.A., Lee C.H., Degertekin M., et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes insights from the Rapamycin-Eluting Stent Evaluation At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol. 41:2003;2093-2099.
43. Arampatzis C.A., Lemos P.A., Tanabe K., et al. Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol. 92:2003;327-329.
44. Daemen J., Lemos P.A., Serruys P.W. Multi-lesion culotte and crush bifurcation stenting with sirolimus-eluting stents long-term angiographic outcome. J Invasive Cardiol. 15:2003;653-656.
45. Colombo A., Orlic D., Stankovic G., et al. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation. 107:2003;2178-2180.
46. Lemos P.A., Saia F., Ligthart J.M.R., et al. Coronary restenosis after sirolimus-eluting stent implantation. Circulation. 108:2003;257-260.
47. Park S.J., Shim W.H., Ho D.S., et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 348:2003;1537-1545.
48. Hong M.K., Mintz G.S., Lee C.W., et al. Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial. Circulation. 107:2003;517-520.
49. O'Neill WW, on behalf of the DELIVER Investigators. Randomized comparison of paclitaxel-coated versus metallic stents for treatment of coronary lesions. Presented at the Annual Scientific Session of the American College of Cardiology, Chicago, Illinois, March 2003.
50. Grube E., Silber S., Hauptmann K.E., et al. TAXUS-I six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 107:2003;38-42.
51. Colombo A., Drzewiecki J., Banning A., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 108:2003;788-794.
52. Tanabe K., Serruys P.W., Grube E., et al. TAXUS-III trial in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 107:2003;559-564.
53. Stone GW. TAXUS-IV: clinical results of the pivotal prospective, multicenter, randomized trial of the polymer-based paclitaxel-eluting stent in patients with de novo lesions. Presented at Transcatheter Cardiovascular Therapeutics 2003, Washington, DC, September 2003.
54. Baim D.S., Wahr D., George B., et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 105:2002;1285-1290.
55. Stone G.W., Rogers C., Hermiller J., et al. Randomized comparison of distal protection with a filter-based catheter and balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 108:2003;548-553.
56. O'Neill WW, on behalf of the TRAP Investigators. A randomized, controlled, multicenter trial of saphenous vein graft intervention with or without distal protection using the TRAP Vascular Filtration System. Presented at the Annual Scientific Session of the American College of Cardiology, Chicago, Illinois, March 2003.
57. Singh M., Rosenschein U., Ho K.K.L., et al. Treatment of saphenous vein bypass grafts with ultrasound thrombolysis. Circulation. 107:2003;2331-2336.
58. Stone G.W., Cox D.A., Babb J., et al. Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries. J Am Coll Cardiol. 42:2003;2007-2013.
59. Schachinger V., Hamm C.W., Munzel T., et al. A randomized trial of polytetrafluoroethylene-membrane covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol. 42:2003;1360-1369.
60. Stankovic G., Colombo A., Presbitero P., et al. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts. Circulation. 108:2003;37-42.
61. Gruberg L., Weissman N.J., Pichard A.D., et al. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. Am Heart J. 145:2003;383-386.
62. Qureshi M., Safian R.D., Grines C.L., et al. Simplified scoring system for predicting mortality after percutaneous coronary intervention. J Am Coll Cardiol. 42:2003;1890-1895.
63. Aspelin P., Aubry P., Fransson S.G., et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 348:2003;491-499.
64. Stone G.W., McCullough P.A., Tumlin J.A., et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy. JAMA. 290:2003;2284-2291.
65. Marenzi G., Marana I., Lauri G., et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 349:2003;1333-1340.
66. Baker C.S.R., Wragg A., Kumar S., et al. A rapid protocol for the prevention of contrast-induced renal dysfunction the RAPPID study. J Am Coll Cardiol. 41:2003;2114-2118.
67. Sarkis A., Badaoui G., Azar R., et al. Gadolinium-enhanced coronary angiography in patients with impaired renal function. Am J Cardiol. 91:2003;974-975.
68. Marso S.P., Giorgi L.V., Johnson W.L., et al. Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention an analysis of 25,223 patients over 20 years. Am Heart J. 145:2003;270-277.
69. Muhlstein J.B., Anderson J.L., Horne B.D., et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J. 146:2003;351-358.
70. 1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. Am J Cardiol. 92:2003;1282-1286.
71. Mazeika P., Prasad N., Bui S., Seidelin P.H. Predictors of angiographic restenosis after coronary intervention in patients with diabetes mellitus. Am Heart J. 145:2003;1013-1021.
72. Takagi T., Yamamuro A., Tamita K., et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus an intravascular ultrasound scanning study. Am Heart J. 146:2003;e5.
73. Piatti P., Di Mario C., Monti L.D., et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation. 108:2003;2074-2081.
74. Mehran R., Aymong E.D., Ashby D.T., et al. Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent. Circulation. 108:2003;1078-1083.
75. Haude M., Konorza T.F.M., Kalnins U., et al. Heparin-coated stent placement for the treatment of stenoses in small coronary arteries of symptomatic patients. Circulation. 107:2003;1265-1270.
76. Kastrati A., Mehilli J., Schuhlen H., et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 350:2004;232-238.
77. Grubel P.A., Cummings C.C., Bell C.R., et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J. 145:2003;239-247.
78. Mueller C., Roskamm H., Neumann F.J., et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol. 41:2003;969-973.
79. Muller I., Besta F., Schulz C., et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation. 108:2003;2195-2197.
80. Lincoff A.M., Bittl J.A., Harrington R.A., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA. 289:2003;853-863.
81. Vakili B.A., Kaplan R.C., Slater J.N., et al. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention. Am J Cardiol. 91:2003;946-950.
82. Klein L.W., Calvin J.E. The dark side of platelet glycoprotein IIb/IIIa receptor inhibitors during percutaneous coronary interventions. Am J Cardiol. 91:2003;1199-1202.
83. Bhatt D.L., Lee B.I., Casterella P.J., et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin study. J Am Coll Cardiol. 41:2003;20-25.
84. Ferguson J.J., Antman E.M., Bates E.R., et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 146:2003;628-634.
85. Douglas JS, Holmes DR, Kereiakes D, et al. Cilostazol for restenosis trial: a randomized, double-blind study following coronary artery stent implantation. Presented at the Annual Scientific Session of the American Heart Association, Orlando, Florida, November 2003.
86. Singh M., Rihal C.S., Selzer F., et al. Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol. 42:2003;1722-1728.
87. Holmes D.R., Selzer F., Johnston J.M., et al. Modeling and risk prediction in the current era of interventional cardiology a report from the National Heart, Lung, and Blood Institute Dynamic Registry. Circulation. 107:2003;1871-1876.
88. Budoff M.J., Achenbach S., Duerinckx A. Clinical utility of computed tomography and magnetic resonance techniques for noninvasive coronary angiography. J Am Coll Cardiol. 42:2003;1867-1878.
89. Kwong R.Y., Schussheim A.E., Rekhraj S., et al. Detecting acute coronary syndrome in the emergency department with cardiac magnetic resonance imaging. Circulation. 107:2003;531-537.
90. Ferencik M., Moselewski F., Ropers D., et al. Quantitative parameters of image quality in multidetector spiral computed tomographic coronary imaging with submillimeter collimation. Am J Cardiol. 92:2003;1257-1262.
91. Faddis M.N., Chen J., Osborn J., et al. Magnetic guidance system for cardiac electrophysiology a prospective trial of safety and efficacy in humans. J Am Coll Cardiol. 42:2003;1952-1958.
92. Britten M.B., Abolmaali N.D., Assmus B., et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI). Circulation. 108:2003;2212-2218.
93. Wollert KC, Meyer GP, Lotz J, et al. Randomized controlled clinical trial of intracoronary autologous bone marrow cell transfer post myocardial infarction. Presented at the Annual Scientific Session of the American Heart Association, Orlando, Florida, November 2003.